Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Nupur Bhatnagar, Vincent Petit, Jayakumar Vadakekolathu, Christian Pinset, Nitin Mahajan, John Dean, Christine Spingola, Laura Arthur, David Boocock, Clare Coveney, John Muth, Jan Baughman, Melissa M Berrien-Elliott, Marc Sitbon, Matthew L. Cooper, Jan Davidson-Moncada, Todd A Fehniger, Sergio Rutella

Blood (2023) 142 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2023-178868

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 466.

https://doi.org/10.1182/blood-2023-184923

Published: 2023

Journal Articles

Mechanisms of Cytokine-Induced NK Cell Therapy: IL-12/15/18 Induce a Unique Transcriptional, Epigenetic, and Functional Human NK Cell Memory Program

Blood (2023) 142 (Supplement 1): 2067.

https://doi.org/10.1182/blood-2023-182435

Published: 2023

Journal Articles

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Amanda F Cashen, Nitin Mahajan, Yanira Ruiz-Heredia, Alejandro Martín-Muñoz, Santiago Barrio, Melissa M Berrien-Elliott, Jan Davidson-Moncada, Todd A Fehniger

Blood (2023) 142 (Supplement 1): 4813.

https://doi.org/10.1182/blood-2023-184986

Published: 2023

Journal Articles

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

Blood (2023) 141 (26): 3153–3165.

https://doi.org/10.1182/blood.2023020100

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic natural killer cell therapy

Melissa M. Berrien-Elliott, Miriam T. Jacobs, Todd A. Fehniger

Blood (2023) 141 (8): 856–868.

https://doi.org/10.1182/blood.2022016200

Published: 2023

Journal Articles

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 7400–7401.

https://doi.org/10.1182/blood-2022-157199

Published: 2022

Journal Articles

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Blood (2022) 139 (13): 1999–2010.

https://doi.org/10.1182/blood.2021011894

Published: 2022

Includes: Supplemental data

Journal Articles

Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

Blood (2022) 139 (11): 1670–1683.

https://doi.org/10.1182/blood.2021013972

Published: 2022

Includes: Supplemental data

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo

Pamela Wong, Carly C. Neal, Lily Chang, Julia A Wagner, Melissa M. Berrien-Elliott, Celia C. Cubitt, Jennifer Tran, David A. Russler-Germain, Nancy D. Marin, Jennifer A Foltz-Stringfellow, Lynne Marsala, Timothy Schappe, Todd A. Fehniger

Blood (2021) 138 (Supplement 1): 194.

https://doi.org/10.1182/blood-2021-149693

Published: 2021

Journal Articles

Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer

Blood (2021) 138 (Supplement 1): 3825.

https://doi.org/10.1182/blood-2021-147370

Published: 2021

Journal Articles

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood (2020) 136 (20): 2308–2318.

https://doi.org/10.1182/blood.2020006619

Published: 2020

Includes: Supplemental data

Journal Articles

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)

Jennifer A Foltz, PhD, Melissa M Berrien-Elliott, PhD, Carly Neal, B.S., Mark Foster, Ethan McClain, Tim Schappe, BS, Sweta Desai, Michelle Becker-Hapak, BS, Amanda F Cashen, MD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 1954.

https://doi.org/10.1182/blood-2019-126004

Published: 2019

Journal Articles

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Carissa Dege, PhD, Katherine H Fegan, MS, J Philip Creamer, IV, BA,BS, Melissa M Berrien-Elliott, PhD, Stephanie A. Luff, PhD, Julia A Wagner, PhD, Paul D. Kingsley, PhD, Kathleen E. McGrath, PhD, Todd A Fehniger, MD PhD, James Palis, MD, Christopher M. Sturgeon, PhD

Blood (2019) 134 (Supplement_1): 2464.

https://doi.org/10.1182/blood-2019-130347

Published: 2019

Journal Articles

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Melissa M Berrien-Elliott, PhD, Margery Gang, Nancy M Marin Agudelo, PhD, Lynne M Marsala, Mark Foster, Carly Neal, B.S., Wong Pamela, B.S., Wei M Meng, B.S., Maximilian M Schaettler, B.S., Tim Schappe, BS, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 869.

https://doi.org/10.1182/blood-2019-127546

Published: 2019

Journal Articles

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Jeffrey J. Bednarski, MD PhD, Clare Zimmerman, MD, Amanda F Cashen, MD, Sweta Desai, Mark Foster, Tim Schappe, BS, Ethan McClain, Michelle Becker-Hapak, BS, Melissa M Berrien-Elliott, PhD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 3307.

https://doi.org/10.1182/blood-2019-126982

Published: 2019

Journal Articles

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Melissa M Berrien-Elliott, PhD, Wong Pamela, B.S., Carly Neal, B.S., Julia A Wagner, PhD, Michelle Becker-Hapak, BS, Tim Schappe, BS, Matthew L. Cooper, PhD, Emily M Mace, PhD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 3237.

https://doi.org/10.1182/blood-2019-129162

Published: 2019

Journal Articles

Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Carissa Dege, PhD, Kathleen E. McGrath, PhD, Melissa M Berrien-Elliott, PhD, Katherine H Fegan, MS, Julia Alexandra Wagner, BS, Todd A Fehniger, MDPhD, James Palis, MD, Christopher Sturgeon, PhD

Blood (2018) 132 (Supplement 1): 1271.

https://doi.org/10.1182/blood-2018-99-119812

Published: 2018

Journal Articles

Memory-Like Natural Killer Cells

Melissa M Berrien-Elliott, PhD, Julia A Wagner, BS, Amanda F Cashen, MD, Todd A Fehniger, MD PhD

Blood (2018) 132 (Supplement 1): SCI-8.

https://doi.org/10.1182/blood-2018-99-109537

Published: 2018

NARROW

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Mechanisms of Cytokine-Induced NK Cell Therapy: IL-12/15/18 Induce a Unique Transcriptional, Epigenetic, and Functional Human NK Cell Memory Program

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

Allogeneic natural killer cell therapy

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo

Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Memory-Like Natural Killer Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only